Load-Bearing Walls vs. Interior Walls
In construction, a load-bearing wall supports the structure of the building. Remove it and the building collapses. A non-load-bearing wall defines a space, provides insulation, holds a door — but the structure stands without it. Renovating a room by removing non-load-bearing walls is straightforward. Removing a load-bearing wall without understanding that it is one is catastrophic.
ME/CFS has the equivalent of load-bearing walls. The disease state is maintained by multiple self-reinforcing mechanisms — “locks” that keep the patient in the disease basin even after the original trigger has resolved. Not all of them are structural. Some are load-bearing. Most are not. The distinction is one of the most important and most overlooked in thinking about treatment [Ch. 16 §Load-Bearing versus Secondary Locks].
1 The distinction
A load-bearing lock is one whose removal is necessary — though not necessarily sufficient — for escape from the disease state. The remaining locks cannot sustain the disease without it. If you can address it, the other mechanisms start to lose their grip.
A secondary lock worsens symptoms and slows recovery but is not structural. The disease can sustain itself without this lock in place. Treating it improves the patient’s experience within the disease state; it does not enable escape.
The building analogy maps directly: removing a load-bearing lock causes the disease attractor to collapse — which is the therapeutic goal. Removing a secondary lock improves the interior without threatening the structure [Ch. 16 §Load-Bearing versus Secondary Locks].
2 Two structural mechanisms
The framework identifies two mechanisms as load-bearing based on their self-sustaining properties and their necessary role in disease maintenance [Ch. 16 §Load-Bearing versus Secondary Locks]:
Epigenetic consolidation. The gene expression program appropriate to sickness — immune activation, metabolic suppression, altered neurotransmitter signalling — can become stabilised through DNA methylation and histone modifications. Once this stabilisation has occurred, the disease state is no longer merely maintained by active signalling; it is written into the chromatin layer. Cells express the disease program not because they are still receiving the original signals but because the record of those signals has been encoded at the level of gene regulation.
This is structural. Addressing the original root cause — clearing a viral reservoir, suppressing the autoimmune response — does not reverse the epigenetic record. The record must itself be addressed, or it will continue encoding the disease state independently. Disease duration is consistently observed to be among the strongest predictors of treatment response in ME/CFS. The framework’s proposed explanation is epigenetic consolidation: it takes time to accumulate, and reversing it takes time. A patient treated within the first year has less consolidated epigenetic disease programming than a patient treated in year five [Ch. 16 §Epigenetic Consolidation].
Autoimmune persistence (GPCR autoantibodies). In patients with autoantibodies targeting G protein-coupled receptors — cell-surface receptors that regulate the autonomic nervous system — the plasma cells producing those antibodies may persist in sanctuaries that are inaccessible to normal immune clearance. As long as production continues, the downstream effects (endothelial dysfunction, immune reprogramming, multi-organ GPCR disruption) are maintained. This is load-bearing in a specific sense: if you address every other mechanism but leave autoantibody production intact, the ongoing assault will — on this model — re-establish the pathological state relatively quickly, though the precise kinetics have not been empirically established in ME/CFS [Ch. 16 §GPCR Autoantibody Cascade].
This second lock is patient-subtype specific. Not all ME/CFS patients have elevated GPCR autoantibodies. For those who do, it is load-bearing. For those who don’t, epigenetic consolidation is, on this framework, the primary structural mechanism to consider.
3 What is not structural
Several prominent disease mechanisms are secondary. They matter — they drive symptoms, they slow recovery, they deepen the disease experience — but they are not structural [Ch. 16 §Load-Bearing versus Secondary Locks]:
Oxidative stress cycle. Reactive oxygen species damage mitochondria, which increases oxidative stress, which damages mitochondria further. This is a real amplifying loop, but it is downstream of the primary energy failure. Correct the upstream mechanisms and the oxidative stress cycle loses its driver [Ch. 16 §Oxidative Stress Vicious Cycle].
Sleep fragmentation. Poor sleep worsens immune function, cognitive symptoms, and pain. Treating it — pharmacologically or otherwise — improves quality of life. But patients whose sleep normalises without addressing upstream mechanisms do not recover. They sleep better within the disease state [Ch. 16 §Downstream Consequences].
Viral reactivation. Antiviral therapy that suppresses EBV or HHV-6 reactivation removes one inflammatory input. But the loop sustaining the disease has other inputs, so the overall structural maintenance is not resolved by this alone. Note that this applies to reactivation as an amplifier; patients with confirmed persistent active viral reservoirs may have a different situation, as discussed in the previous article [Ch. 16 §Viral Reactivation and Immune Exhaustion].
Gut dysbiosis. Microbiome disruption amplifies immune activation and systemic inflammation. It is real; it is worth treating. It is not load-bearing [Ch. 16 §Amplifier Mechanisms].
4 Symptom salience and structural importance
Secondary locks often produce the most immediately visible symptoms. Sleep fragmentation, pain, and cognitive dysfunction are what patients report most urgently, and treating them is appropriate — but the therapeutic expectation must be calibrated. Improving a secondary lock does not create a path to recovery; it improves the patient’s experience within the disease. That has value, and it is not the same as structural treatment.
Load-bearing locks, particularly epigenetic consolidation, often produce no direct, immediately perceptible symptom. A patient cannot feel that their gene expression is being maintained by methylation patterns. There is no symptom that corresponds to “epigenetic disease encoding.” The pain and fatigue are produced by the downstream consequences, not by the consolidation mechanism itself.
This creates a systematic mismatch between symptom salience and structural importance. The mechanisms that hurt most are often secondary. The mechanisms that maintain the disease often produce no direct perceptible signal.
Effective treatment should include addressing the load-bearing structure — not because symptoms don’t matter, but because addressing symptoms alone does not create a path to recovery. Where structural treatments are not yet available or validated, symptom management remains the appropriate clinical priority and the only currently available option for most patients [Ch. 16 §Treatment Implications of the Causal Hierarchy].
5 Treatment order
The load-bearing vs. secondary distinction implies a specific order of priorities. The first question is which locks are load-bearing for this patient — subtype matters, since GPCR autoantibodies are structural only in the autoimmune subtype. Load-bearing locks then become the primary treatment objective, even when they produce less immediate symptomatic relief. Secondary locks are worth treating for quality of life, with calibrated expectations about their contribution to recovery rather than escape from the disease state.
Sequence also matters, according to the framework’s model. In the epigenetic case, energy restoration and inflammation reduction are predicted to need to precede or accompany epigenetic intervention, because the model expects that reversing methylation without reducing the signals that drive it would lead to rapid re-consolidation [Ch. 33 §Lock Removal Sequence Dependence]. This sequencing prediction has not yet been tested in clinical trials; treating in the wrong order is not merely predicted to be suboptimal — the model suggests it could be self-defeating.
Previous article in this series: Four Doors, One Disease (2026-04-09)
Next: Root Cause ≠ Treatment Priority — the counterintuitive insight that the most causally fundamental mechanism isn’t necessarily the best treatment target